Leucovorin and oxaliplatin (FOLFOX) has a superior response rate versus doxorubicin among Asian sorafenib-naive patients.  We aimed to retrospectively review the outcome of 20 consecutive patients treated with FOLFOX at a single European center.


 In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation.
FOLFOX
Sorafenib is the only standard therapy for advanced hepatocellular carcinoma, but has a low response rate.  Leucovorin and oxaliplatin (FOLFOX) has a superior response rate versus doxorubicin among Asian sorafenib-naive patients.  Patients had symptomatic disease burdens unlikely to regress with sorafenib or had no proven treatment options (sorafenib-refractory or recurrence post liver transplantation).


 One sorafenib-refractory patient had a complete response and two liver transplant patients experienced partial responses. 
sorafenib